The Friday Five Scoreboard

Catalyst

On October 9, 2026 SpaceX announced a definitive agreement to acquire the nationwide 800 MHz spectrum portfolio held by Grain Management, up to 14 megahertz of paired low band spectrum previously bought from T-Mobile, so Starlink Mobile can operate as a major American mobile carrier, and said it intends to run standard wireless equipment on towers, rooftops and other structures. The transaction needs approval from the Federal Communications Commission. Crown Castle rose 15.60 percent that session while T-Mobile fell, and has gone sideways in the four sessions since.

Why It Mattered

A fourth national carrier needing tower space is the best thing that can happen to a company that owns towers, and the cross section proves the attribution: Prologis fell 1.82 percent and Equinix fell 1.47 percent in the same sector, so this was not the fall in long rates, and the three carrier customers fell between 4 and 8 percent, which a rate move would never do.

Risk Note

Crown Castle has signed nothing and is not a party to the transaction, which still needs regulatory approval. SpaceX said it intends to operate its own terrestrial infrastructure, and that could mean its own structures rather than leased space.

Catalyst

On October 13, 2026 UnitedHealth reported 112.7 billion dollars of revenue and adjusted earnings of 4.69 dollars a share against a consensus near 4.12, cut its medical care ratio to 88.4 percent from 89.9 percent, and raised full year 2026 adjusted guidance to at least 20.50 dollars a share. The same release reported 2027 Medicare Advantage Star ratings with at least 69 percent of members in four plus Star plans.

Why It Mattered

The timing separates the company from the sector. The shares went nowhere on the day of the release and then rose 4.73 percent on October 14, the day the Nasdaq fell 1.88 percent. The market read the quarter and paid for it with money it took out of technology.

Risk Note

Beat and Raise is the weakest catalyst type in this newsletter's own record, averaging 1.43 percent below the S&P 500 a month later across 35 matured picks. In a rotation week a defensive name also gets paid twice, and the second payment is the one that gets taken back.

Catalyst

On October 12, 2026 Regeneron released 84 week results from the Phase 3 OPTIMA extension of Pasatru in adults with fibrodysplasia ossificans progressiva: zero new heterotopic ossification lesions between weeks 56 and 84 against nine detected by scan on placebo, and one flare up at the higher dose against seventeen on placebo. The drug was approved in August 2026 and is the first approved treatment for the condition.

Why It Mattered

Zero is a rare word in clinical data and this is confirmation rather than hope, on a drug already approved. But the attribution is thin and published as thin: health care rose 5.37 percent as a sector and Regeneron beat its own sector by only 0.8 and 0.5 percentage points on the two days it moved, so roughly two of its 7.68 percent is company specific.

Risk Note

The most extended pick in the issue at 92.7 percent of its 52 week high after a 39.9 percent year, on confirmatory data in an ultra rare condition that cannot re rate a company this size by itself.

Catalyst

On October 13, 2026 the European Commission conditionally cleared the Kimberly-Clark acquisition of Kenvue, requiring the sale of its entire European tampon and feminine hygiene portfolio including Kotex. The same day the company filed early tender results on the exchange of Kenvue notes, stating the acquisition is expected to close in the fourth quarter of 2026 and that the exchange offers expire October 27, 2026. The shares fell 0.49 percent that session and then rose 4.69 percent on October 15.

Why It Mattered

On October 15 consumer staples rose 0.72 percent and Kimberly-Clark rose 4.69 percent, so about four points of that day was the company rather than the sector, two days after the news. An acquirer rising on its own deal being approved is unusual, and it says the price had been carrying real risk the deal would be blocked or cost too much to fund.

Risk Note

The clearance is conditional on completing a sale of the European feminine hygiene brands, and a remedy that falls through reopens it. The real problem is integration of a 40 billion dollar plus acquisition, financed partly in stock, by a company whose shares are down 13.1 percent over a year.

Catalyst

On October 14, 2026 BlackRock reported record assets under management of 15.488 trillion dollars with quarterly net inflows of 205.5 billion dollars, organic base fee growth of 11 percent annualised and a ninth consecutive quarter at or above its 5 percent long term target, adjusted diluted earnings of 15.93 dollars a share up 38 percent, and revenue of 7.752 billion dollars up 19 percent.

Why It Mattered

The rest of the sector settles the attribution. Bank of America fell 3.56 percent, Citigroup 3.80 percent, Morgan Stanley 2.85 percent and State Street 4.28 percent around their own reports, so this was a bid for these results and not for financials. In the week the market stopped paying for companies building artificial intelligence capacity, it paid for the one that earns a fee on everybody's allocation decision.

Risk Note

Fee revenue is a percentage of asset values, so a sustained drawdown cuts the base that produced the record. The shares are still down 4.3 percent over a year after a record quarter, which says the market treats 15.488 trillion as a cyclical peak.